NCT02210858

Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders

Public trial-level signal summary for this oncology Phase 2 record.

Record overview

Status and phase

Status: COMPLETED

Phase: PHASE1, PHASE2

Sponsor: National Cancer Institute (NCI)

Condition: Accelerated Phase of Disease, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Chronic Phase of Disease, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Recurrent Disease

Signal summary

Public flags

Status signal: Low Signal

Timeline signals: stale_update_signal

Results signal: Completed No Results Found Signal

Operational burden: rare_population_signal

Stopped reason

Context when available

No stop reason available in the current public record.